Navigation Links
Indevus Pharmaceuticals Announces First Quarter Fiscal 2009 Financial Results
Date:2/4/2009

endence on third parties for supplies, particularly for histrelin, manufacturing, marketing, and clinical trials; risks associated with being a manufacturer of some of our products; risks associated with contractual agreements, particularly for the manufacture and co-promotion of SANCTURA and SANCTURA XR and the manufacture of NEBIDO, VANTAS, SUPPRELIN LA and VALSTAR; reliance on intellectual property and having limited patents and proprietary rights; dependence on market exclusivity, changes in reimbursement policies and/or rates for SANCTURA, SANCTURA XR, VANTAS, SUPPRELIN LA, DELATESTRYL and any future products; acceptance by the healthcare community of our approved products and product candidates; uncertainties relating to clinical trials, regulatory approval and commercialization of our products, particularly SANCTURA XR, NEBIDO, and VALSTAR; product liability and insurance uncertainties; risks relating to the Redux-related litigation; need for additional funds and corporate partners, including for the development of our products; history of operating losses and expectation of future losses; uncertainties relating to controls over financial reporting; difficulties in managing our growth; valuation of our Common Stock; risks related to repayment of debts; risks related to increased leverage; general worldwide economic conditions and related uncertainties; and other risks. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

Additional Important Information

This press release is for informational purposes only and does not constitute a recommendation, an offer to purchase or a solicitation of an offer to sell securities of the Company. The tender offer is being made pursuant to a tender offer statement on Schedule TO (including the offer to purchase, letter of transmittal and other related tender offer materials, w
'/>"/>

SOURCE Indevus Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine news :

1. Indevus Pharmaceuticals Announces Definitive Merger Agreement With Endo Pharmaceuticals
2. Endo Pharmaceuticals to Acquire Indevus Pharmaceuticals
3. Indevus Pharmaceuticals Announces Third Quarter Fiscal 2008 Financial Results
4. Indevus Pharmaceuticals Provides Update on NEBIDO(R) NDA Status
5. Indevus Pharmaceuticals Licenses European Rights for VANTAS(R) to Orion Corporation
6. Indevus Pharmaceuticals Announces Retirement Plans For Its CEO and Chairman
7. Indevus To Announce First Quarter Fiscal 2008 Financial Results On Thursday, February 7, 2008
8. Indevus Pharmaceuticals To Present at RBC Capital Markets Conference
9. FDA Accepts New Drug Application for NEBIDO(R) Submitted by Indevus
10. Indevus Pharmaceuticals to Present at Upcoming Investor Conferences
11. Skinvisible Signs Dermatology Agreement With RHEI Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... Hastings and Hastings, a discount accident lawyer in Phoenix, Arizona, ... number of visitors to its new Phoenix personal injury website. ... as well as auto accident cases and slip & fall ... others. Having served the state of Arizona for over 30 ... when it comes to dedicated and focused personal injury legal ...
(Date:9/19/2014)... NH 9/18/14) A leading Dartmouth researcher, working with The ... a paper published today in the Journal of ... increase the risk of melanoma. , "For the first ... length of these telomeres play a part in the ... study Mark Iles, PhD, School of Medicine at the ...
(Date:9/19/2014)... 19, 2014 Visiting Nurse Association (VNA) ... health care, hospice and palliative care and community-based care, ... Opening Bell yesterday at the New York Stock Exchange. ... and social entrepreneur to care for immigrant families suffering ... always worked to meet the urgent healthcare needs of ...
(Date:9/19/2014)... NY (PRWEB) September 19, 2014 According ... manufacturers of the embattled blood-thinner Xarelto, named as defendants ... of Common Pleas, have moved the court to dismiss ... do not have sufficient connection with Philadelphia.* The cases ... et al. (No. 140304328; Pa. Comm. Pls., Philadelphia Cty.), ...
(Date:9/19/2014)... (PRWEB) September 19, 2014 Boston Scientific ... mesh lawsuit ( http://www.transvaginalmeshlawsuithelp.com/ ) that is scheduled ... month, Bernstein Liebhard LLP reports. According to ... Court, the company asserts that claims involving its Solyx ... Practice and Remedies Code, a section of which shields ...
Breaking Medicine News(10 mins):Health News:Hastings And Hastings Announces a Record Number of Visitors to Its New Phoenix Personal Injury Website 2Health News:Melanoma risk found to have genetic determinant 2Health News:NJ Largest Home Healthcare Not-for-Profit Joins Deutsche Bank to Ring NYSE Opening Bell 2Health News:NJ Largest Home Healthcare Not-for-Profit Joins Deutsche Bank to Ring NYSE Opening Bell 3Health News:Xarelto Makers Seek Dismissal of Cases Brought in Philadelphia, Notes Rottenstein Law Group LLP 2Health News:Xarelto Makers Seek Dismissal of Cases Brought in Philadelphia, Notes Rottenstein Law Group LLP 3Health News:Transvaginal Mesh Lawsuit Defendant Moves For Summary Judgment in Case Scheduled for Upcoming Texas Trial, Bernstein Liebhard LLP Reports 2Health News:Transvaginal Mesh Lawsuit Defendant Moves For Summary Judgment in Case Scheduled for Upcoming Texas Trial, Bernstein Liebhard LLP Reports 3Health News:Transvaginal Mesh Lawsuit Defendant Moves For Summary Judgment in Case Scheduled for Upcoming Texas Trial, Bernstein Liebhard LLP Reports 4
... has apparently told his neighbours in the US, that charges ... due to negligence, have been dropped. Dr Patel, dubbed Dr. ... Hospital, Queensland. ,The government of Peter Beattie, Premier ... US. According to an AAP news report, Dr. Patel has ...
... said 22 cases of Chikungunya disease were confirmed in ... the 20 villages in Kolhapur district from where an ... found 22 cases from only 12 villages, which tested ... Pune's National Institute of Virology (NIV)," said Maharashtra health ...
... confessed to aborting over 250 female fetuses, adding he has lost ... his nursing home over the last decade. ,A.K. Singh ... in Pataudi town near here and discovered the dumped fetuses from ... has confessed that he has aborted more than 250 unborn female ...
... Moved by the plight of a one-year-old child whose ... , the Delhi High Court has asked the government ... not be paid to his parents for his upbringing. ... a division bench of Justices T.S. Thakur and S.N. ...
... describes how an impaired anti-inflammatory response plays a role ... ,Published in the Journal of Immunology, the study ... bind to specific receptors on cells and set off ... ,Interleukins, interferons, tumour necrosis factors, and some growth ...
... obesity, high blood pressure, high cholesterol, and inactivity are a ... 24. , The study was conducted by ... Reilly and Jesse Morrell, at the University of New Hampshire. ... from more than 800 undergraduates enrolled in a general-education nutrition ...
Cached Medicine News:Health News:Quack of Gurgaon Confesses of Aborting 250 Female Fetuses 2Health News:Child Seeks Compensation for Medical Negligence 2Health News:Cytokine Resistance Contributes to Pathology of Type 2 Diabetes 2
(Date:9/19/2014)... 2014 Today, iHealth Lab Inc. announced it has ... for its first institutional round of funding. The strategic ... reach, accelerate growth and innovation, and invest in additional ... Xiaomi Ventures will join iHealth,s board of directors, bringing ... ecommerce. "We are very pleased to have ...
(Date:9/19/2014)... , Sept. 19, 2014 /PRNewswire-iReach/ -- ... to 2020″, provides key market data ... devices market. The report provides value, ... volume (in units) within market categories ... Sigmoidoscopes, Esophagoscopes & Gastroscopes, Duodenoscopes, Laparoscopes, ...
(Date:9/19/2014)... 19, 2014 Research ... the addition of the "Global Gynecological ... offering.      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ... classified into wide categories based on their ... treatment of different gynecological conditions that affect ...
Breaking Medicine Technology:iHealth Raises $25 Million to Fuel Growth and Global Market Share 2United States General Surgery Devices Market to 2020 - Endoscopy, Bariatric Surgery, Aesthetic Lasers and Energy, Biopsy Devices, Hernia Repair, Non-Vascular Stents 2United States General Surgery Devices Market to 2020 - Endoscopy, Bariatric Surgery, Aesthetic Lasers and Energy, Biopsy Devices, Hernia Repair, Non-Vascular Stents 3United States General Surgery Devices Market to 2020 - Endoscopy, Bariatric Surgery, Aesthetic Lasers and Energy, Biopsy Devices, Hernia Repair, Non-Vascular Stents 4United States General Surgery Devices Market to 2020 - Endoscopy, Bariatric Surgery, Aesthetic Lasers and Energy, Biopsy Devices, Hernia Repair, Non-Vascular Stents 5Global Gynecological Devices Market 2014-2018: Key Vendors are Bayer, Boston Scientific, CooperSurgical, Ethicon, Hologic, Medtronic, Olympus and Stryker 2Global Gynecological Devices Market 2014-2018: Key Vendors are Bayer, Boston Scientific, CooperSurgical, Ethicon, Hologic, Medtronic, Olympus and Stryker 3
... Choices for This Common and Successful Surgery, ... the September issue of Mayo Clinic Health Letter. ... wish. Reprinting is allowed for a,fee. Mayo Clinic ... information as your editorial policies permit: Visit, http://www.HealthLetter.MayoClinic.com ...
... Clinical Lab,Products magazine features Biomoda, Inc. ... its proprietary early lung cancer screening,assay as ... the cancer diagnostic,technology. The August national magazine ... assay,s simplicity that leads to large scale ...
Cached Medicine Technology:September 2008 Mayo Clinic Health Letter Highlights Cataract Removal, Severe Headache and Dual Energy X-Ray Imaging 2September 2008 Mayo Clinic Health Letter Highlights Cataract Removal, Severe Headache and Dual Energy X-Ray Imaging 3September 2008 Mayo Clinic Health Letter Highlights Cataract Removal, Severe Headache and Dual Energy X-Ray Imaging 4Clinical Lab Products Magazine Features Biomoda 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: